Two Cancer Researchers Elected to Top Science Academy

When cancer spreads to bones or treatments cause muscle loss, patients face challenges that extend far beyond the tumor itself. Two researchers at The University of Texas MD Anderson Cancer Center just earned one of science's highest honors for changing how we understand and treat these problems.

Theresa Guise, M.D., and Stephanie Watowich, Ph.D., were elected fellows of the American Association for the Advancement of Science this March. Since 1874, AAAS has recognized scientists making exceptional contributions to research and society, with fewer than 500 researchers chosen worldwide each year.

Guise has spent her career uncovering how cancer and its treatments affect bones, muscles, and metabolism. Her research revealed the molecular drivers behind cancer-induced bone destruction and discovered how weakened bones send signals that contribute to muscle loss and metabolic problems. These insights are helping doctors develop treatments that protect patients' strength and quality of life across multiple cancer types.

Watowich focuses on the immune system's ability to detect and fight cancer. Her team discovered how key immune cells develop and function, leading to breakthroughs in understanding why some patients respond beautifully to immunotherapy while others don't. Her work has advanced a promising new dendritic cell therapy and is helping make immunotherapy safer and more effective for more patients.

Both scientists are dedicated mentors who have trained dozens of the next generation of cancer researchers. Together, they've published hundreds of studies that are changing patient care today.

The Ripple Effect

The impact of their work extends far beyond the lab. When Guise identifies how to prevent bone fractures in cancer patients, those discoveries help people maintain independence and avoid painful complications. When Watowich reveals why certain immune cells fight tumors more effectively, oncologists gain new tools to personalize treatments and reduce harmful side effects.

MD Anderson's collaborative environment accelerates these discoveries by connecting clinicians directly with scientists. Insights from patient care guide lab experiments, while laboratory breakthroughs quickly move into clinical testing. This cycle of innovation means discoveries reach patients faster.

With this honor, 72 MD Anderson faculty members have now been elected AAAS Fellows. Each recognition represents years of dedication to solving cancer's most challenging problems and improving outcomes for patients worldwide.